Showing results (31-40 of 505) with videos related to
Sort By:
Pageof 51
Current Drug Targets. Cardiovascular & Haematological Disorders|December 20, 2003
An update on new anticoagulantsLori-Ann Linkins, Jeffrey I WeitzNature Reviews. Cardiology|March 14, 2012
Anticoagulation therapy. Dabigatran and risk of myocardial infarctionJohn W Eikelboom, Jeffrey I WeitzJournal of Thrombosis and Haemostasis : JTH|October 13, 2020
New anticoagulants: Moving beyond the direct oral anticoagulantsJames C Fredenburgh, Jeffrey I WeitzArteriosclerosis, Thrombosis, and Vascular Biology|February 26, 2008
New anticoagulants for treatment of venous thromboembolismPeter L Gross, Jeffrey I WeitzJournal of Thrombosis and Haemostasis : JTH|March 6, 2026
Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA ProgramJeffrey I Weitz, Robert A Harrington, Thrombosis and Haemostasis|July 10, 2015
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulantsJeffrey I Weitz, Charles V PollackJournal of Thrombosis and Haemostasis : JTH|January 22, 2025
Exosite crosstalk in thrombinJames C Fredenburgh, Jeffrey I WeitzJournal of Thrombosis and Haemostasis : JTH|July 10, 2023
Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trialsJohn W Eikelboom, Jeffrey I WeitzBlood|January 10, 2020
Novel antithrombotic strategies for treatment of venous thromboembolismJeffrey I Weitz, Noel C ChanPolskie Archiwum Medycyny Wewnetrznej|September 6, 2016
Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulantsJeffrey I Weitz, Iqbal H JafferPageof 51